Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

National Intersectoral MHPSS Emergency Preparedness and Response Plan: In the Context of the Risk of War on Lebanon

 
In response to the escalating situation and war on Lebanon, the Ministry of Public Health (MoPH) has developed and is currently implementing with all stakeholders the:
“National Intersectoral MHPSS Emergency Preparedness and Response Plan: In the Context of the Risk of War on Lebanon "

Developed through a collaborative approach by the National Mental Health Programme (NMHP) with the support of the World Health Organization, UNICEF, and all MHPSS Stakeholders (please refer to the action plan for a full list), this comprehensive plan outlines a proactive approach to anticipating, mitigating, and responding to the psychosocial impacts by focusing on early intervention and support to minimize the adverse effects on individuals, healthcare personnel and communities. It underscores the commitment of the MoPH and the NMHP to safeguard mental health and respond timely and effectively to the psychosocial needs of all populations residing in Lebanon during times of crisis while promoting their resilience.

Key Features of the Plan:
  • Continuity of MHPSS Services: The plan highlights actions to ensure the continued availability and accessibility of MHPSS services across Lebanon.
  • Assurance of Psychotropic Medications: The plan emphasizes ensuring the continuous supply and access to psychotropic medications to all old and new beneficiaries.
  • Communication and Messaging: The plan prioritizes the development and dissemination of key messages and tips on topics related to mental health and well-being that would promote community resilience.
  • Training and Capacity Building: The plan places a strong emphasis on training healthcare professionals and frontline responders in MHPSS principles and practices to provide effective support to service users and providers.
The MoPH is implementing this action plan with all stakeholders, including governmental bodies, local authorities and municipalities, non-governmental organizations, healthcare providers, frontliners, and the international community - Please do reach out if your organization is interested to join in implementing this crucial plan and working together to ensure the mental health and psychosocial support of Lebanon’s residents during times of adversity.

Kindly find a selection of valuable links below:
    4
    ...
ATC Name B/G Ingredients Dosage Form Price
A02BC03 LPZ-30 G Lansoprazole - 30mg 30mg Capsule, delayed release 360,150 L.L
G04BX14 LEJAM G Dapoxetine (hydrochloride) - 30mg 30mg Tablet, film coated 1,269,931 L.L
N06AX21 LOXYT 30 G Duloxetine HCl - 30mg 30mg Capsule, delayed release 716,716 L.L
J05AF05 LAMIVUDINE ARROW G Lamivudine - 300mg 300mg Tablet, coated 7,850,907 L.L
J01XX08 LINEZOLID ARROW G Linezolide - 600mg/300ml 2mg/ml Injectable solution 13,282,147 L.L
L01BB04 LITAK 10 B Cladribine - 2mg/ml 2mg/ml Injectable solution 130,295,163 L.L
A07DA03 LOPERAMIDE ARROW LAB G Loperamide HCl - 2mg 2mg Capsule 442,124 L.L
N05BA06 LORAZEPAM G Lorazepam - 2mg 2mg Tablet, scored 485,063 L.L
C10AA08 LIVAZO B Pitavastatin - 2mg 2mg Tablet, film coated 1,558,857 L.L
L04AX04 LENALIDOMIDE SPC G Lenalidomide - 25mg 25mg Capsule, hard 87,161,381 L.L
L04AX04 LENALIDOMIDE STRAGEN G Lenalidomide - 25mg 25mg Capsule 33,314,752 L.L
L04AX04 LENOMA G Lenalidomide - 25mg 25mg Capsule, hard 15,343,847 L.L
N03AX09 LAMICTAL B Lamotrigine - 25mg 25mg Tablet 1,088,270 L.L
N03AX09 LAMOTRIGINE ARROW LAB G Lamotrigine - 25mg 25mg Tablet, dispersible/ chewable 556,351 L.L
N03AX09 LAMOTRIGINE BIOGARAN G Lamotrigine - 25mg 25mg Tablet, dispersible 595,322 L.L
L01ED05 LORBRENA B Lorlatinib - 25mg 25mg Tablet 134,559,469 L.L
L04AX04 LENOMA G Lenalidomide - 25mg 25mg Capsule, hard L.L
L04AX04 LEDOBOOK 25 G Lenalidomide - 25mg 25mg Capsule 67,887,540 L.L
L04AX04 LENALIDOMIDE ARROW G Lenalidomide - 25mg 25mg Capsule 26,651,802 L.L
L04AX04 LENALIDOMIDE NEAPOLIS G Lenalidomide - 25mg 25mg Capsule 76,719,234 L.L
N03AX14 LEPITAM G Levetiracetam - 250mg 250mg Tablet 700,078 L.L
N03AX14 LEVETIRACETAM ARROW LAB G Levetiracetam - 250mg 250mg Tablet, film coated, breakable 1,243,054 L.L
N03AX14 LEVETIRACETAM BIOGARAN G Levetiracetam - 250mg 250mg Tablet, coated, scored 1,350,562 L.L
N03AX14 LEVIPRAM 250 G Levetiracetam - 250mg 250mg Tablet, film coated 1,087,873 L.L
D01BA02 LAMIFEN G Terbinafine HCl - 250mg 250mg Tablet 245,923 L.L
D01BA02 LAMINOX G Terbinafine HCl - 250mg 250mg Tablet 725,675 L.L
J05AB01 LOVRAK-JULPHAR G Aciclovir - 250mg 250mg Injectable lyophilised powder 278,175 L.L
C03CA01 LASIMIDE G Furosemide - 20mg/2ml 20mg/2ml Injectable solution 1,300,328 L.L
C10AA05 LIPODAR G Atorvastatin (calcium) - 20mg 20mg Tablet, film coated 2,236,154 L.L
C10AA05 LIPONORM G Atorvastatin (calcium) - 20mg 20mg Tablet, film coated 1,249,774 L.L
    4
    ...
Sitemap
© Copyrights reserved to Ministry of Public Health 2025